India Glycols Limited has announced its financial results for the quarter and year ended March 31, 2026, showing substantial year-on-year growth. The company reported annual revenue from operations of ₹9,826.20 crore on a standalone basis, with a net profit for the year reaching ₹282.33 crore. These figures reflect a strong performance across key segments, driven by consistent growth in the Potable Spirits and Bio-Fuel divisions.
Financial Performance Overview
For the financial year ended March 31, 2026, India Glycols Limited recorded a standalone revenue of ₹9,826.20 crore, compared to ₹9,037.82 crore in the previous year. The standalone net profit after tax stood at ₹282.33 crore, a significant improvement from ₹180.38 crore reported for the year ended March 31, 2025. On a consolidated basis, the company achieved an annual revenue of ₹9,826.63 crore and a net profit of ₹292.76 crore.
Quarterly Performance Highlights
In the final quarter (Q4) of the 2026 financial year, the company generated a standalone revenue from operations of ₹2,361.40 crore. The net profit for the quarter was ₹110.28 crore, showing strong profitability compared to the same period in the previous fiscal year. This quarter was characterized by robust operational efficiency, reflected in an EBIDTA of ₹203.42 crore for the standalone results.
Operational Segment Analysis
The company’s diverse portfolio continues to drive value. The Potable Spirits segment remains the largest revenue contributor, generating ₹6,946.43 crore annually. The Bio-Fuel segment also showed significant expansion, with revenues climbing to ₹1,469.93 crore for the year. Meanwhile, Bio-based Specialities and Performance Chemicals reported annual revenues of ₹1,202.07 crore.
Corporate Developments and Dividends
During the fiscal year, India Glycols completed a preferential issue of 51,03,765 equity shares at a price of ₹915 per share, bolstering its capital base. Furthermore, the Board of Directors approved an interim dividend of ₹7.50 per equity share for the 2025-26 fiscal year. The company is also actively progressing with its restructuring plans, including the demerger of its Bio Pharma undertaking into Ennature Bio Pharma Limited and the Spirits & Biofuel undertaking into IGL Spirits Limited, with an appointed date of April 1, 2026.
Source: BSE
